Search

Your search keyword '"Natalello, G."' showing total 77 results

Search Constraints

Start Over You searched for: Author "Natalello, G." Remove constraint Author: "Natalello, G."
77 results on '"Natalello, G."'

Search Results

1. A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

2. Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function

3. Distinguishing features of autoimmune gastritis depending on previous H. pylori infection or positivity to anti-parietal cell antibodies: Results from the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO)

4. AB1183 THE USE OF MYCOPHENOLATE MOFETIL IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS IS ASSOCIATED WITH A REDUCED RISK OF VASCULAR COMPLICATIONS REQUIRING PHARMACOLOGICAL INTERVENTION UPGRADES

5. POS1479-HPR TRAVEL DISTANCE TO TERTIARY HEALTHCARE REFLECTS DISEASE SEVERITY AND MEDICATION ACCESS IN SYSTEMIC SCLEROSIS PATIENTS: INSIGHTS FROM THE ITALIAN SPRING REGISTRY

6. OP0296 ARRHYTHMIC BURDEN, MYOCARDIAL MARKERS, AND LONG-TERM SURVIVAL IN DISTINCT CARDIAC MAGNETIC RESONANCE SUBSETS OF SYSTEMIC SCLEROSIS

7. AB1496 MICROCIRCULATION CHARACTERIZATION IN ANOREXIA NERVOSA PATIENTS WITH RAYNAUD’S PHENOMENON

8. POS1418 ESOPHAGEAL MUCOSAL EROSIONS CAN PREDICT THE DETERIORATION OF LUNG FUNCTION OVER A FOUR-YEAR FOLLOW-UP PERIOD AND LONG-TERM MORTALITY IN PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SCLERODERMA

9. POS0030 SAFETY AND PRELIMINARY EFFICACY OF CD19 CAR-T CELL TREATMENT IN RHEUMATIC DISEASE- DATA FROM THE FIRST PART OF THE PHASE I/II CASTLE BASKET STUDY

10. OC.04.7: A ONE-YEAR FOLLOW-UP STUDY ON CHECKPOINT INHIBITORINDUCED COLITIS: RESULTS FROM A EUROPEAN CONSORTIUM

11. Chronic related group classification system as a new public health tool to predict risk and outcome of COVID-19 in patients with systemic rheumatic diseases: A population-based study of more than forty thousand patients

14. POS0948 PATTERNS OF DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS PATIENTS WITH INTERSTITIAL LUNG DISEASE

15. Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients

18. POS1251 INCIDENCE AND OUTCOMES OF SARS-CoV-2 INFECTION IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: A POPULATION-BASED STUDY OF MORE THAN FOUR MILLION INHABITANTS IN THE LAZIO ITALIAN REGION

19. AB0704 LOW BODY MASS INDEX IN PATIENTS WITH RAYNAUD PHENOMENON IS ASSOCIATED WITH ENLARGED CAPILLARIES AND REDUCTION IN CAPILLARY DENSITY AT NAILFOLD VIDEOCAPILLAROSCOPY

21. Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function

22. Post-COVID-19 global health strategies: the need for an interdisciplinary approach

23. Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement

24. Seroprevalence of anti‐SARS‐CoV‐2 IgG antibodies in children with household exposure to adults with COVID‐19: Preliminary findings

27. POS0891 IMPROVED SURVIVAL IN SYSTEMIC SCLEROSIS PATIENTS DURING LAST DECADE: CURRENT FINDINGS AND COMPARISON WITH DIFFERENT PREVIOUS ITALIAN COHORTS

28. Residual respiratory impairment after COVID-19 pneumonia

29. Reply to: Individuality of the composition of the human microbiota

30. OP0009 DERIVATION AND VALIDATION OF THE SCLERODERMA LUNG 3-STAGE INDEX (SL3SI), A NEW FUNCTIONAL INDEX FOR INTERSTITIAL LUNG DISEASE WITH PROGNOSTIC IMPLICATIONS

31. AB0757 ASSOCIATION BETWEEN DEPRESSIVE SYMPTOMS AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH PSORIATIC ARTHRITIS

36. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings

37. No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic

38. Post-COVID-19 global health strategies: the need for an interdisciplinary approach

39. Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status

40. Sarilumab use in severe SARS-CoV-2 pneumonia

41. Assessment of neurological manifestations in hospitalized patients with COVID-19

Catalog

Books, media, physical & digital resources